Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.
Auteurs : Franzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E Jaar : 2022 Journal : Breast Cancer Res Treat
Authors' Reply To the Letters to the Editor by Puklin et al and by Iyengar and Ligibel.
Auteurs : Martel S, Lambertini M, de Azambuja E Jaar : 2022 Journal : J Natl Compr Canc Netw
How we treat patients with metastatic HER2-positive breast cancer.
Auteurs : Nader-Marta G, Martins-Branco D, de Azambuja E Jaar : 2022 Journal : ESMO Open
Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated with Radiation Therapy and Trastuzumab.
Auteurs : Bachir B, Anouti S, Jaoude JA, Kayali M, Tfayli A, de Azambuja E, Poortmans P, Zeidan Y Jaar : 2022 Journal : Int J Radiat Oncol Biol Phys
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY
Auteurs : Gelber Rd, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M Jaar : 2022 Journal : Eur J Cancer